研究者業績

冨永 薫

トミナガ カオル  (Kaoru Tominaga)

基本情報

所属
自治医科大学 医学部生化学講座構造生化学部門 教授
学位
博士(医学)(1994年3月 自治医科大学)

J-GLOBAL ID
201401018168107794
researchmap会員ID
B000237522

外部リンク

論文

 61
  • Satoshi Ohta, Kenji Tago, Katsumi Kasashima, Masayuki Ebina, Kaoru Tominaga
    International Journal of Molecular Sciences 26(21) 10388-10388 2025年10月25日  査読有り最終著者責任著者
    Ras gene mutations are frequently observed in many types of cancers. However, there are currently no effective anticancer drugs against Ras-induced cancers. Therefore, identifying the downstream effectors of the Ras signaling pathway can facilitate the development of promising novel therapeutic approaches. We previously showed that oncogenic Ras induces the expression of the receptor tyrosine kinase c-Mer proto-oncogene tyrosine kinase (MerTK) in an interleukin-1 family member NF-HEV/IL-33-dependent manner and that IL-33 and MerTK contribute to oncogenic Ras-induced cell migration. In the present study, we purified the MerTK complex from NIH-3T3 cells transformed by the expression of oncogenic Ras, H-Ras (G12V). Mass spectrometric analysis identified STK38 (also known as NDR1) as a candidate binding partner for MerTK. STK38 is a serine/threonine protein kinase that plays diverse roles in normal and cancerous cells. In addition to MerTK knockdown, STK38 knockdown effectively attenuated the H-Ras (G12V)-induced migration of NIH-3T3 cells. STK38 kinase activity is required for oncogenic Ras-induced cell migration and MerTK tyrosine phosphorylation. Furthermore, MerTK or STK38 knockdown attenuated the activation of Rac1 and Cdc42. Taken together, these results revealed a novel role for STK38 in oncogenic Ras-induced enhanced cell migration, which may be useful for developing novel therapeutic strategies targeting Ras-mutated cells.
  • Shin-ichiro Kawaguchi, Kazuya Sato, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Kaoru Tominaga, Hitoshi Endo, Tom Kouki, Nobuhiko Ohno, Yoshinobu Kanda
    Cell Death & Disease 16(1) 2025年10月21日  査読有り
    Abstract Leukemia cells are consistently subjected to higher oxidative stress than normal cells. To mitigate reactive oxygen species (ROS) overload, which can trigger various forms of cell death, leukemia cells employ a robust antioxidant defense system and maintain redox homeostasis. Recent evidence suggests that dimethyl fumarate (DMF), a derivative of fumarate, inactivates the antioxidant glutathione (GSH), thereby inducing oxidative stress and metabolic dysfunction, eventually leading to cell death in cancer cells. In this study, we observed that DMF decreases the GSH/oxidated GSH ratio and increases intracellular ROS levels, the extent of which is closely correlated with cell death, in acute myeloid leukemia (AML) cell lines. DMF reduced the mitochondrial membrane potential and oxidative phosphorylation (OXPHOS), effects that were almost fully restored by the antioxidant N-acetylcysteine, suggesting that these responses are ROS-dependent. Electron microscopy and inhibition assays revealed that apoptosis, rather than necroptosis or ferroptosis, is the predominant form of cell death of AML cells following DMF treatment. Notably, the combination of DMF and the BCL-2 selective BH3-mimetic venetoclax induced marked cell death in AML cells, including venetoclax-refractory BCL-2 low expressing U937 and acquired venetoclax-resistant MOLM-14 cells. This combination also caused greater mitochondrial depolarization and a more profound reduction in OXPHOS activity than either agent alone. Collectively, our findings indicate that DMF exerts potent anti-leukemia activity in AML cells and sensitizes cells to venetoclax treatment by synergistically disrupting mitochondrial integrity through ROS accumulation.
  • Kazuya Sato, Shin‐ichiro Kawaguchi, Junko Izawa, Takashi Ikeda, Kiyomi Mashima, Norihito Takayama, Hiroko Hayakawa, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda
    European Journal of Immunology 55(4) 2025年4月19日  査読有り
    ABSTRACT Recent evidence indicates that the TCA cycle metabolite fumarate plays a specific role in modulating signaling pathways in immune cells. We have previously shown that dimethyl fumarate (DMF) reduces glutathione (GSH) activity and causes the accumulation of cellular reactive oxygen species (ROS), thereby compromising effector immune responses and metabolic activities in activated T‐cells. However, the precise mechanism by which DMF modulates T‐cell signaling pathways remains to be elucidated. This study demonstrates that DMF inhibits T‐cell proliferation, independent of T‐cell receptor (TCR) engagement, and this response is fully reversible by replenishing GSH. Immunoblot analysis showed that DMF had different impacts on TCR downstream signaling by decreasing MYC expression while promoting the phosphorylation of Akt and Erk1/2. Cell cycle analysis demonstrated that exposure to DMF led to negative regulation of cell cycle‐related proteins and induced T‐cells into G0/G1 arrest, which was also rescued by antioxidants. Several genes related to GSH synthesis were upregulated at the same time, suggesting that a potential compensatory response may occur to reduce oxidative burst following DMF treatment. Our results suggest that DMF‐mediated oxidative stress alters a range of cell signaling pathways, including MYC, leading to cell cycle arrest and a defective proliferative response of T‐cells during activation.
  • Hirofumi Nakano, Kazuya Sato, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Takashi Ikeda, Shin-Ichiro Kawaguchi, Kiyomi Mashima, Kento Umino, Kaoru Morita, Ryoji Ito, Nobuhiko Ohno, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda
    ImmunoHorizons 8(3) 228-241 2024年3月1日  査読有り
    Although the role of aerobic glycolysis in activated T cells has been well characterized, whether and how fatty acids (FAs) contribute to donor T cell function in allogeneic hematopoietic stem cell transplantation is unclear. Using xenogeneic graft-versus-host disease (GVHD) models, this study demonstrated that exogenous FAs serve as a crucial source of mitochondrial respiration in donor T cells in humans. By comparing human T cells isolated from wild-type NOD/Shi-scid-IL2rγnull (NOG) mice with those from MHC class I/II-deficient NOG mice, we found that donor T cells increased extracellular FA uptake, the extent of which correlates with their proliferation, and continued to increase FA uptake during effector differentiation. Gene expression analysis showed the upregulation of a wide range of lipid metabolism-related genes, including lipid hydrolysis, mitochondrial FA transport, and FA oxidation. Extracellular flux analysis demonstrated that mitochondrial FA transport was required to fully achieve the mitochondrial maximal respiration rate and spare respiratory capacity, whereas the substantial disruption of glucose supply by either glucose deprivation or mitochondrial pyruvate transport blockade did not impair oxidative phosphorylation. Taken together, FA-driven mitochondrial respiration is a hallmark that differentiates TCR-dependent T cell activation from TCR-independent immune response after hematopoietic stem cell transplant.
  • Kaoru Tominaga, Eiji Sakashita, Katsumi Kasashima, Kenji Kuroiwa, Yasumitsu Nagao, Naoki Iwamori, Hitoshi Endo
    International Journal of Molecular Sciences 24(3) 2113-2113 2023年1月20日  査読有り筆頭著者責任著者
    Epigenetic regulation via epigenetic factors in collaboration with tissue-specific transcription factors is curtail for establishing functional organ systems during development. Brain development is tightly regulated by epigenetic factors, which are coordinately activated or inactivated during processes, and their dysregulation is linked to brain abnormalities and intellectual disability. However, the precise mechanism of epigenetic regulation in brain development and neurogenesis remains largely unknown. Here, we show that Tip60/KAT5 deletion in neural stem/progenitor cells (NSCs) in mice results in multiple abnormalities of brain development. Tip60-deficient embryonic brain led to microcephaly, and proliferating cells in the developing brain were reduced by Tip60 deficiency. In addition, neural differentiation and neuronal migration were severely affected in Tip60-deficient brains. Following neurogenesis in developing brains, gliogenesis started from the earlier stage of development in Tip60-deficient brains, indicating that Tip60 is involved in switching from neurogenesis to gliogenesis during brain development. It was also confirmed in vitro that poor neurosphere formation, proliferation defects, neural differentiation defects, and accelerated astrocytic differentiation in mutant NSCs are derived from Tip60-deficient embryonic brains. This study uncovers the critical role of Tip60 in brain development and NSC maintenance and function in vivo and in vitro.
  • Kiyomi Mashima, Kazuya Sato, Takashi Ikeda, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Shin‐Ichiro Kawaguchi, Hirofumi Nakano, Takashi Nagayama, Kento Umino, Kaoru Morita, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda
    British Journal of Haematology 2022年2月15日  査読有り
  • Rintaro Kuroda, Kaoru Tominaga, Katsumi Kasashima, Kenji Kuroiwa, Eiji Sakashita, Hiroko Hayakawa, Tom Kouki, Nobuhiko Ohno, Kensuke Kawai, Hitoshi Endo
    PLOS ONE 16(7) e0255355-e0255355 2021年7月28日  査読有り責任著者
    Mitochondrial dysfunction is significantly associated with neurological deficits and age-related neurological diseases. While mitochondria are dynamically regulated and properly maintained during neurogenesis, the manner in which mitochondrial activities are controlled and contribute to these processes is not fully understood. Mitochondrial transcription factor A (TFAM) contributes to mitochondrial function by maintaining mitochondrial DNA (mtDNA). To clarify how mitochondrial dysfunction affects neurogenesis, we induced mitochondrial dysfunction specifically in murine neural stem cells (NSCs) by inactivating Tfam. Tfam inactivation in NSCs resulted in mitochondrial dysfunction by reducing respiratory chain activities and causing a severe deficit in neural differentiation and maturation both in vivo and in vitro. Brain tissue from Tfam-deficient mice exhibited neuronal cell death primarily at layer V and microglia were activated prior to cell death. Cultured Tfam-deficient NSCs showed a reduction in reactive oxygen species produced by the mitochondria. Tfam inactivation during neurogenesis resulted in the accumulation of ATF4 and activation of target gene expression. Therefore, we propose that the integrated stress response (ISR) induced by mitochondrial dysfunction in neurogenesis is activated to protect the progression of neurodegenerative diseases.
  • Yasufumi Kawasaki, Kazuya Sato, Kiyomi Mashima, Hirofumi Nakano, Takashi Ikeda, Kento Umino, Kaoru Morita, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda
    TRANSPLANTATION AND CELLULAR THERAPY 27(3) 2021年3月  査読有り
  • Satsuki Miyata, Kaoru Tominaga, Eiji Sakashita, Masashi Urabe, Yoshiyuki Onuki, Akira Gomi, Takashi Yamaguchi, Makiko Mieno, Hiroaki Mizukami, Akihiro Kume, Keiya Ozawa, Eiju Watanabe, Kensuke Kawai, Hitoshi Endo
    Scientific reports 9(1) 9787-9787 2019年7月5日  査読有り責任著者
    Gliomas with Isocitrate dehydrogenase 1 (IDH1) mutation have alterations in several enzyme activities, resulting in various metabolic changes. The aim of this study was to determine a mechanism for the better prognosis of gliomas with IDH mutation by performing metabolomic analysis. To understand the metabolic state of human gliomas, we analyzed clinical samples obtained from surgical resection of glioma patients (grades II-IV) with or without the IDH1 mutation, and compared the results with U87 glioblastoma cells overexpressing IDH1 or IDH1R132H. In clinical samples of gliomas with IDH1 mutation, levels of D-2-hydroxyglutarate (D-2HG) were increased significantly compared with gliomas without IDH mutation. Gliomas with IDH mutation also showed decreased intermediates in the tricarboxylic acid cycle and pathways involved in the production of energy, amino acids, and nucleic acids. The marked difference in the metabolic profile in IDH mutant clinical glioma samples compared with that of mutant IDH expressing cells includes a decrease in β-oxidation due to acyl-carnitine and carnitine deficiencies. These metabolic changes may explain the lower cell division rate observed in IDH mutant gliomas and may provide a better prognosis in IDH mutant gliomas.
  • Naoki Iwamori, Kaoru Tominaga, Tetsuya Sato, Kevin Riehle, Tokuko Iwamori, Yasuyuki Ohkawa, Cristian Coarfa, Etsuro Ono, Martin M Matzuk
    Proceedings of the National Academy of Sciences of the United States of America 113(37) E5408-15 2016年9月13日  査読有り
    Splicing can be epigenetically regulated and involved in cellular differentiation in somatic cells, but the interplay of epigenetic factors and the splicing machinery during spermatogenesis remains unclear. To study these interactions in vivo, we generated a germline deletion of MORF-related gene on chromosome 15 (MRG15), a multifunctional chromatin organizer that binds to methylated histone H3 lysine 36 (H3K36) in introns of transcriptionally active genes and has been implicated in regulation of histone acetylation, homology-directed DNA repair, and alternative splicing in somatic cells. Conditional KO (cKO) males lacking MRG15 in the germline are sterile secondary to spermatogenic arrest at the round spermatid stage. There were no significant alterations in meiotic division and histone acetylation. Specific mRNA sequences disappeared from 66 germ cell-expressed genes in the absence of MRG15, and specific intronic sequences were retained in mRNAs of 4 genes in the MRG15 cKO testes. In particular, introns were retained in mRNAs encoding the transition proteins that replace histones during sperm chromatin condensation. In round spermatids, MRG15 colocalizes with splicing factors PTBP1 and PTBP2 at H3K36me3 sites between the exons and single intron of transition nuclear protein 2 (Tnp2). Thus, our results reveal that MRG15 is essential for pre-mRNA splicing during spermatogenesis and that epigenetic regulation of pre-mRNA splicing by histone modification could be useful to understand not only spermatogenesis but also, epigenetic disorders underlying male infertile patients.
  • Mashiko T, Sakashita E, Kasashima K, Tominaga K, Kuroiwa K, Nozaki Y, Matsuura T, Hamamoto T, Endo H
    The Journal of biological chemistry 291(29) 14996-15007 2016年7月  査読有り
  • 益子 貴史, 坂下 英司, 笠嶋 克巳, 黒岩 憲二, 冨永 薫, 松浦 徹, 遠藤 仁司
    日本生化学会大会・日本分子生物学会年会合同大会講演要旨集 88回・38回 [3P1250]-[3P1250] 2015年12月  
  • Kaoru Tominaga
    Pathobiology of aging & age related diseases 5 27743-27743 2015年  査読有り筆頭著者最終著者責任著者
    Cellular senescence is a state of permanent growth arrest and is thought to play a pivotal role in tumor suppression. Cellular senescence may play an important role in tumor suppression, wound healing, and protection against tissue fibrosis in physiological conditions in vivo. However, accumulating evidence that senescent cells may have harmful effects in vivo and may contribute to tissue remodeling, organismal aging, and many age-related diseases also exists. Cellular senescence can be induced by various intrinsic and extrinsic factors. Both p53/p21 and p16/RB pathways are important for irreversible growth arrest in senescent cells. Senescent cells secret numerous biologically active factors. This specific secretion phenotype by senescent cells may largely contribute to physiological and pathological consequences in organisms. Here I review the molecular basis of cell cycle arrest and the specific secretion phenotype in cellular senescence. I also summarize the current knowledge of the role of cellular senescence in vivo in physiological and pathological settings.
  • Satoshi Yamamoto, Yasumitsu Nagao, Kenji Kuroiwa, Yoji Hakamata, Masaru Ichida, Fumiko Saito-Ohara, Kaoru Tominaga, Hitoshi Endo
    TRANSGENIC RESEARCH 23(5) 757-765 2014年10月  査読有り
  • Syuichi Tetsuka, Kaoru Tominaga, Eriko Ohta, Kenji Kuroiwa, Eiji Sakashita, Katsumi Kasashima, Toshiro Hamamoto, Michito Namekawa, Mitsuya Morita, Shinsuke Natsui, Tatsuo Morita, Keiko Tanaka, Yoshihisa Takiyama, Imaharu Nakano, Hitoshi Endo
    JOURNAL OF THE NEUROLOGICAL SCIENCES 335(1-2) 48-57 2013年12月  査読有り
  • Kotaro Kawanishi, Mitsuya Morita, Keiichi Nakahara, Syuichi Tetsuka, Tom Kouki, Kaoru Tominaga, Hitoshi Endo, Takashi Yashiro, Keiko Tanaka, Imaharu Nakano
    Brain and Nerve 65(11) 1401-1405 2013年11月  査読有り
  • Akimoto C, Sakashita E, Kasashima K, Kuroiwa K, Tominaga K, Hamamoto T, Endo H
    Biochimica et biophysica acta 1830(3) 2728-2738 2013年3月  査読有り
  • Chizuru Akimoto, Eiji Sakashita, Katsumi Kasashima, Kenji Kuroiwa, Kaoru Tominaga, Toshiro Hamamoto, Hitoshi Endo
    Biochimica et Biophysica Acta - General Subjects 1830(3) 2728-2738 2013年3月  査読有り
  • Akimoto C, Sakashita E, Kasashima K, Kuroiwa K, Tominaga K, Hamamoto T, Endo H
    Biochimica et biophysica acta 1830(3) 2728-2738 2013年  査読有り
  • Kaoru Tominaga, Olivia M. Pereira-Smith
    CURRENT DRUG TARGETS 13(13) 1593-1602 2012年12月  査読有り筆頭著者責任著者
  • Viviana I. Perez, Lisa A. Cortez, Christie M. Lew, Marisela Rodriguez, Celeste R. Webb, Holly Van Remmen, Asish Chaudhuri, Wenbo Qi, Shuko Lee, Alex Bokov, Wilson Fok, Dean Jones, Arlan Richardson, Junji Yodoi, Yiqiang Zhang, Kaoru Tominaga, Gene B. Hubbard, Yuji Ikeno
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES 66(12) 1286-1299 2011年12月  査読有り
  • AndreAna N. Pena, Kaoru Tominaga, Olivia M. Pereira-Smith
    EXPERIMENTAL CELL RESEARCH 317(11) 1534-1540 2011年7月  査読有り
  • Meizhen Chen, Olivia M. Pereira-Smith, Kaoru Tominaga
    STEM CELL RESEARCH 7(1) 75-88 2011年7月  査読有り最終著者責任著者
  • Martrat G, Maxwell CM, Tominaga E, Porta-de-la-Riva M, Bonifaci N, Gómez-Baldó L, Bogliolo M, Lázaro C, Blanco I, Brunet J, Aguilar H, Fernández-Rodríguez J, Seal S, Renwick A, Rahman N, Kühl J, Neveling K, Schindler D, Ramírez MJ, Castellà M, Hernández G, EMBRACE, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Davidson R, Ong KR, Cook J, Douglas F, Hodgson S, Brewer C, Morrison PJ, Porteous M, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Pasini B, Ottini L, Putignano AL, Savarese A, Bernard L, Radice P, Healey S, Spurdle A, Chen X, Beesley J, kConFab, Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Asperen CJ, Bodmer D, Ausems MG, van Os TA, Blok MJ, Meijers-Heijboer HE, Hogervorst FB, HEBON, Goldgar DE, Buys S, John EM, Miron A, Southey M, Daly MB, BCFR, SWE-BRCA, Harbst K, Borg A, Rantala J, Barbany-Bustinza G, Ehrencrona H, Stenmark-Askmalm M, Kaufman B, Laitman Y, Milgrom R, Friedman E, Domchek SM, Nathanson KL, Rebbeck TR, Johannsson OT, Couch FJ, Wang X, Fredericksen Z, Cuadras D, Moreno V, Pientka FK, Depping R, Caldés T, Osorio A, Benítez J, Bueren J, Heikkinen T, Nevanlinna H, Hamann U, Torres D, Caligo MA, Godwin AK, Imyanitov EN, Janavicius R, GEMO Study Collaborators, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Verny-Pierre C, Castera L, de Pauw A, Bignon YJ, Uhrhammer N, Peyrat JP, Vennin P, Ferrer SF, Collonge-Rame MA, Mortemousque I, McGuffog L, Chenevix-Trench G, Pereira-Smith OM, Antoniou AC, Cerón J, Tominaga K, Surrallés J, Pujana MA
    Breast cancer research : BCR 13 R40 2011年4月  査読有り責任著者
  • Mahlke MA, Cortez LA, Ortiz MA, Rodriguez M, Uchida K, Shigenaga MK, Lee S, Zhang Y, Tominaga K, Hubbard GB, Ikeno Y
    Pathobiology of aging & age related diseases 1 2011年  査読有り
  • Hongjun Zhang, Yishi Li, Junsheng Yang, Kaoru Tominaga, Olivia M. Pereira-Smith, John Tower
    EXPERIMENTAL GERONTOLOGY 45(11) 825-833 2010年11月  査読有り
  • Reini F. Luco, Qun Pan, Kaoru Tominaga, Benjamin J. Blencowe, Olivia M. Pereira-Smith, Tom Misteli
    SCIENCE 327(5968) 996-1000 2010年2月  査読有り
  • Kaoru Tominaga, Emiko Tominaga, Michael J. Ausserlechner, Olivia M. Pereira-Smith
    EXPERIMENTAL CELL RESEARCH 316(1) 92-102 2010年1月  査読有り筆頭著者責任著者
  • Meizhen Chen, Kaoru Tominaga, Olivia M. Pereira-Smith
    AGING, CANCER, AND AGE-RELATED DISEASES: COMMON MECHANISM? 1197 134-141 2010年  査読有り
  • Ahmed Sabbah, Te Hung Chang, Rosalinda Harnack, Victoria Frohlich, Kaoru Tominaga, Peter H. Dube, Yan Xiang, Santanu Bose
    NATURE IMMUNOLOGY 10(10) 1073-U49 2009年10月  査読有り
  • Meizhen Chen, Masumi Takano-Maruyama, Olivia M. Pereira-Smith, Gary O. Gaufo, Kaoru Tominaga
    JOURNAL OF NEUROSCIENCE RESEARCH 87(7) 1522-1531 2009年5月  査読有り最終著者責任著者
  • Sandra N. Garcia, Bhakti M. Kirtane, Andrej J. Podlutsky, Olivia M. Pereira-Smith, Kaoru Tominaga
    FEBS LETTERS 581(27) 5275-5281 2007年11月  査読有り最終著者責任著者
  • BR Bowman, CM Moure, BM Kirtane, RL Welschhans, K Tominaga, OM Pereira-Smith, FA Quiocho
    STRUCTURE 14(1) 151-158 2006年1月  査読有り
  • K Tominaga, MM Matzuk, OM Pereira-Smith
    MOLECULAR AND CELLULAR BIOLOGY 25(12) 4873-4880 2005年6月  査読有り筆頭著者責任著者
  • K Tominaga, B Kirtane, JG Jackson, Y Ikeno, T Ikeda, C Hawks, Smith, JR, MM Matzuk, OM Pereira-Smith
    MOLECULAR AND CELLULAR BIOLOGY 25(8) 2924-2937 2005年4月  査読有り筆頭著者責任著者
  • K Tominaga, DM Magee, MM Matzuk, OM Pereira-Smith
    MOLECULAR AND CELLULAR BIOLOGY 24(19) 8366-8373 2004年10月  査読有り筆頭著者責任著者
  • K Tominaga, JK Leung, P Rookard, J Echigo, Smith, JR, OM Pereira-Smith
    JOURNAL OF BIOLOGICAL CHEMISTRY 278(49) 49618-49624 2003年12月  査読有り筆頭著者
  • K Tominaga, OM Pereira-Smith
    GENE 294(1-2) 215-224 2002年7月  査読有り筆頭著者責任著者
  • K Tominaga, A Olgun, Smith, JR, OM Pereira-Smith
    MECHANISMS OF AGEING AND DEVELOPMENT 123(8) 927-936 2002年4月  査読有り筆頭著者
  • H Takai, K Tominaga, N Motoyama, YA Minamishima, H Nagahama, T Tsukiyama, K Ikeda, K Nakayama, N Nakanishi, K Nakayama
    GENES & DEVELOPMENT 14(12) 1439-1447 2000年6月  査読有り筆頭著者
  • S Saito, M Matsuura, K Tominaga, T Kirikae, M Nakano
    EUROPEAN JOURNAL OF BIOCHEMISTRY 267(1) 37-45 2000年1月  査読有り
  • K Tominaga, S Saito, M Matsuura, K Funatogawa, H Matsumura, M Nakano
    JOURNAL OF LEUKOCYTE BIOLOGY 66(6) 974-980 1999年12月  査読有り筆頭著者責任著者
  • K Tominaga, H Morisaki, Y Kaneko, A Fujimoto, T Tanaka, M Ohtsubo, M Hirai, H Okayama, K Ikeda, M Nakanishi
    JOURNAL OF BIOLOGICAL CHEMISTRY 274(44) 31463-31467 1999年10月  査読有り筆頭著者
  • Y Kaneko, N Watanabe, H Morisaki, H Akita, A Fujimoto, K Tominaga, M Terasawa, A Tachibana, K Ikeda, M Nakanishi
    ONCOGENE 18(25) 3673-3681 1999年6月  査読有り
  • M Nakano, K Tominaga, S Saito, F Kirikae, SN Lin, CL Fumero, Ojima, I, T Kirikae
    JOURNAL OF ENDOTOXIN RESEARCH 5(1-2) 102-106 1999年  査読有り
  • M Tanikawa, K Yamada, K Tominaga, H Morisaki, Y Kaneko, K Ikeda, M Suzuki, T Kiho, K Tomokiyo, K Furuta, R Noyori, M Nakanishi
    JOURNAL OF BIOLOGICAL CHEMISTRY 273(29) 18522-18527 1998年7月  査読有り
  • T Kirikae, F Kirikae, S Saito, K Tominaga, H Tamura, Y Uemura, T Yokochi, M Nakano
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 42(5) 1015-1021 1998年5月  査読有り

MISC

 33

共同研究・競争的資金等の研究課題

 8